#Sweden #Immunovia #Lund #pancreatic cancer #Warrants

Immunovia Sets Exercise Price for Warrant Series TO 2

Immunovia AB, a leading diagnostic company focused on early detection of pancreatic cancer, has recently announced the exercise price for its warrant series TO 2. The price has been determined at SEK 0.46 per warrant, with the exercise period commencing on January 2, 2025 and concluding on January 16, 2025. The trading for these warrants will continue up to January 14, 2025.

This announcement comes along with an impressive commitment from existing investors. In addition to the SEK 0.8 million subscription intentions from Immunovia’s CEO and board members, an external commitment from professional investors has amounted to approximately SEK 36.3 million, conditional on approval at an extraordinary general meeting. In total, these commitments provide a significant cushion of about 65% of the warrant programme, equating to roughly SEK 37.2 million.

Jeff Borcherding, CEO of Immunovia, emphasized the importance of these arrangements, stating, "Securing the TO2 warrants at favorable terms lowers our risk and allows us to reach critical milestones. The funds generated will support our preparations to launch our next-generation test in the US market by the second half of 2025. Additionally, these resources will facilitate clinical studies essential for gaining reimbursement for our test."

Back during August to September 2024, Immunovia conducted a rights issue of units, which included shares, warrants TO 2, and warrants TO 3. Each TO 2 warrant gives its holder the right to subscribe to one new share of Immunovia. If all warrants are successfully exercised, the company expects to garner about SEK 57.2 million before issuance costs from this Warrant Programme.

The calculation for the subscription price of the warrants is set at 70% of the volume-weighted average price of the company's shares on Nasdaq Stockholm during the period of December 12 - December 27, 2024. The determined price of SEK 0.46 per share reflects this average pricing metric.

Subscription and Commitment Breakdown

The company’s recent updates revealed not only the interest from internal stakeholders but also strategic commitments from external investors, which total around SEK 0.1 million from subscriptions and guarantee commitments of SEK 36.3 million. This assortment of commitments equates to 63.4% of the Warrant Programme.

Detailed subscription instructions have been provided for different classifications of warrant holders. For holders with nominee-registered warrants, it is crucial they follow their nominee's process to exercise their warrants on time. Those with directly registered holdings need to ensure their applications are submitted by January 16, 2025, alongside timely payments to avoid expiration.

Trading activities for TO 2 will cease on January 14, 2025, marking a pivotal moment for both investors and the company as it pushes forward with its market initiatives.

Future Outlook

As Immunovia gears up for the next steps, the potential outcomes of these efforts include an expanded shareholder base and improved market liquidity. By focusing on securing exercise warrants and addressing predisposed commitments, the company’s directives indicate a strategic shift towards bolstering its institutional and professional investor relationships. The current market validation will be instrumental in advancing its clinical goals and overall mission of enhancing survival rates in pancreatic cancer through innovative diagnostic testing.

In summary, these recent developments not only reflect Immunovia’s commitment to meeting critical milestones but also signify a broader movement toward enhancing the company's operational efficacy and market positioning in the vital field of pancreatic cancer diagnostics. For more details, Immunovia shareholders and interested parties are advised to stay updated through the company’s official communications.